Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease

Real-world Safety and Efficacy Data of Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease: the Experience of the Hellenic Cooperative Oncology Group

Patients with cancer and concurrent autoimmune diseases (AID) have been universally excluded from clinical trials evaluating immunotherapy. Data on the safety and efficacy of checkpoint inhibitors in patients with underlying AID is limited. The investigators performed a retrospective multicenter review of medical records of patients with diverse tumor types and underlying AID who received checkpoint inhibitors at Departments of Oncology, affiliated with the Hellenic Cooperative Oncology Group (HeCOG). The primary endpoint was progression-free survival (PFS).

Inclusion Criteria:

• 18 years or older
• Patients with cancer
• Patients with autoimmune disease
• Treated at HeCOG-affiliated Departments of Oncology
• Early-stage or metastatic

Exclusion Criteria:

• diagnosis of the autoimmune disease after initiation of immunotherapy